Search Result

Results for "

CDK9 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (36) AAK1 (1) Apoptosis (8) Atg8/LC3 (1) ATTECs (1) Autophagy (1) c-Myc (2) Caspase (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (2) Ephrin Receptor (1) FGFR (1) FLT3 (1) HIV (2) IRAK (1) Itk (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (7) MAP4K (1) MELK (1) Molecular Glues (3) p38 MAPK (1) PARP (1) PROTACs (24) Reference Standards (1) Target Protein Ligand-Linker Conjugates (2) ULK (1) Wee1 (1)
By Research Areas:	Cancer (40) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (3)

By Targets:

CDK (36)

AAK1 (1)

Apoptosis (8)

Atg8/LC3 (1)

ATTECs (1)

Autophagy (1)

c-Myc (2)

Caspase (1)

DNA/RNA Synthesis (1)

E3 Ligase Ligand-Linker Conjugates (2)

Ephrin Receptor (1)

FGFR (1)

FLT3 (1)

HIV (2)

IRAK (1)

Itk (1)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (7)

MAP4K (1)

MELK (1)

Molecular Glues (3)

p38 MAPK (1)

PARP (1)

PROTACs (24)

Reference Standards (1)

Target Protein Ligand-Linker Conjugates (2)

ULK (1)

Wee1 (1)

By Research Areas:

Cancer (40)

Infection (2)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (3)

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123937

THAL-SNS-032 Maximum Cited Publications 10 Publications Verification	PROTACs CDK	Cancer
THAL-SNS-032 is a selective *CDK9* degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN) .

HY-18340

(R)-CR8 1 Publications Verification CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-103628

*PROTAC CDK9* Degrader-1** 2 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective *CDK9* degrader.

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-130709

*PROTAC CDK2/9 Degrader-1*	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC₅₀=62 nM) and *CDK9* (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .

HY-173523

KI-CDK9d-32	PROTACs CDK c-Myc	Cancer
KI-CDK9d-32 is a highly selective and potent *CDK9* PROTAC degrader (DC₅₀: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .

HY-112811

*PROTAC CDK9* degrader-2**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compound 11c) is a potent and selective *CDK9* degrader based on PROTAC, with an IC₅₀ of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, *CDK9* PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-168518

*PROTAC CDK9* degrader-9**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-9 (compound 29) is a highly selective and efficient *CDK9* degrader based on PROTAC technology. PROTAC CDK9 degrader-9 can be used in anti-cancer research .

HY-18340A

(R)-CR8 trihydrochloride 1 Publications Verification CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

HY-178861

dCDK9-202	PROTACs CDK Caspase PARP Apoptosis	Cancer
dCDK9-202 a potent CDK9 PROTAC degrader with an DC₅₀ value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .

HY-149964

*PROTAC CDK9* degrader-7**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-7 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

HY-115728

*PROTAC CDK9* degrader-4**	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious *CDK9* degrader for targeting transcription regulation.

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs .

HY-170978

*PROTAC CDK9* degrader-11**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC degrader for *CDK9* with DC₅₀ of 1.09 nM. PROTAC CDK9 degrader-11 exhibits cytotoxicity in multi small cell lung cancer cell with IC₅₀ of nanomolar levels. PROTAC CDK9 degrader-11 arrests cell cycle at G0/G1 phase, inhibits the cell invasion in DMS114 and DMS53 cell. PROTAC CDK9 degrader-11 exhibits antitumor efficacy in NCI-H446 xenograft mouse models .(Pink: ligand for target protein CDK9 ligand 3 (HY-170979); Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56 (HY-W247437))

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual CDK2 and CDK5 degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .

HY-149962

*PROTAC CDK9* degrader-5**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-5 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-176451

CDK9 degrader-1	CDK	Cancer
CDK9 degrader-1 (Compound AZ-9) is a selective *CDK9* degrader (DC₅₀: 0.4073 µM). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuses with lysosomes to degrade CDK9 and its partner protein Cyclin T1 (DC₅₀: 1.215 µM). CDK9 degrader-1 induces caspase 3-mediated apoptosis. CDK9 degrader-1 has antitumor activity in a mouse HCT116 xenograft model .

HY-168896

CDK9 autophagic degrader 1	CDK ATTECs	Cancer
CDK9 autophagic degrader 1 (Compound 28) is a ATTEC degrader that can be used to degrade *CDK9* and also affects the levels of the associated Cyclin T1. CDK9 autophagic degrader 1 shows over 80% *CDK9* inhibition rate at 100 nM . ( Pink: LC3B ligand (HY-168897); Black: linker (HY-W017758); Blue: target protein ligand (HY-10008); linker + target protein ligand (HY-168898))

HY-148521

*PROTAC FLT3/CDK9* degrader-1**	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-149963

*PROTAC CDK9* degrader-6**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-6 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-149870

*PROTAC CDK9* degrader-8**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC₅₀ value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer .

HY-156795

*PROTAC CDK9/CycT1 Degrader-2*	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-W247437

E3 ligase Ligand 56	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 56 is the ligand for E3 ligase Cereblon and can be used for syntheisis of PROTAC CDK9 degrader-11 (HY-170978) .

HY-181231

*PROTAC CDK9* degrader-12**	PROTACs CDK HIV DNA/RNA Synthesis	Infection
PROTAC CDK9 degrader-12 is a selective CDK9 PROTAC degrader with a DC₅₀ of 23 nM. PROTAC CDK9 degrader-12 induces proteasome-dependent degradation of CDK9, blocks CDK9-mediated HIV-1 transcriptional elongation, and reduces HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is applicable to research related to HIV-1 infection .

HY-177780

Cyclin K degrader 2	Molecular Glues CDK Apoptosis	Cancer
Cyclin K degrader 2 is a molecular glucose degrading agent that targets the cyclin K protein. Cyclin K degrader 2 has inhibitory activity against CDK1 and *CDK9. Cyclin K degrader* 2 causes a decrease in RNA polymerase II Ser2 phosphorylation levels, downregulation of DNA damage response gene expression, accumulation of DNA damage, G1 phase arrest of the cell cycle, and apoptosis. Cyclin K degrader 2 can be used for cancer research .

HY-103628R

*PROTAC CDK9* Degrader-1 (Standard)**	Reference Standards PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 (Standard) is the analytical standard of PROTAC CDK9 Degrader-1 (HY-103628). This product is intended for research and analytical applications. PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective CDK9 degrader.

HY-164906

TMX-2138	CDK PROTACs	Cancer
TMX-2138 is a CDKs PROTAC degrader, with IC₅₀s of 8.7 nM, 10.9 nM, 7.0 nM and 25.7 nM for CDK1/cyclinB, CDK2/cyclinA, CDK5/p25 and CDK9/cyclinT1, respectively. TMX-2138 promotes ubiquitination and degradation of CDKs. TMX-2138 can be used for the research of ovarian cancer (Pink: CDKs ligand (HY-151071); Blue: E3 ligase CRBN ligand (HY-14658); Black: linker (HY-W008352)) .

HY-178452

*PROTAC CDK4/6/9 degrader* 1**	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6/9 degrader 1 is a CDK4/6/9 PROTAC degrader. PROTAC CDK4/6/9 degrader 1 degrades CDK4, CDK6, and *CDK9* in TNBC cells and inhibits TNBC cell proliferation. PROTAC CDK4/6/9 degrader 1 induces G1 phase arrest, promotes apoptosis, and suppresses cell migration and invasion in TNBC cells. PROTAC CDK4/6/9 degrader 1 can be used for the study of triple-negative breast cancer (TNBC). (Pink: CDK4/6/9 ligand (HY-168440), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-178512), E3 ligase ligand-linker conjugate (HY-178515)) .

HY-130850

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

HY-168892

LC3B recruiter 2	Atg8/LC3 Autophagy	Cancer
LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to *CDK9* inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the *CDK9* and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity .

HY-178862

CDK9 ligand-Linker Conjugate	Target Protein Ligand-Linker Conjugates	Cancer
CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202 (HY-178861). dCDK9-202 is a potent CDK9 PROTAC degrader with anti-tumor activity .

HY-130852

CDK9-IN-11	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

HY-170979

CDK9 ligand 3	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9 ligand 3 is the ligand for *CDK9* and can be used for synthesis of PROTAC degrader PROTAC CDK9 degrader-11 (HY-170978) .

HY-156083

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC CDK9/CycT1* Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

HY-115729A

(R)-PROTAC CDK9 ligand-1	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

HY-168897

LC3B ligand 1	Ligands for Target Protein for PROTAC	Others
LC3B ligand 1 is a ligand for the target protein of PROTAC and can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-168898

1,3-Propanediol-SNS-032	Target Protein Ligand-Linker Conjugates	Others
1,3-Propanediol-SNS-032 is a target protein ligand and linker conjugate, which can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .

HY-182810

CDK9 ligand 5	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9 ligand 5 (Compound 48) is a *CDK9* ligand. CDK9 ligand 5 can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC CDK9, such as PROTAC CDK9 degrader-9 (HY-168518). CDK9 ligand 5 can be used in cancer research .

HY-181275

CDK9 ligand 4	Ligands for Target Protein for PROTAC CDK HIV	Infection
CDK9 ligand 4 is a *CDK9* ligand. As a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), CDK9 ligand 4 serves for the development and design of PROTAC CDK9 degraders, such as PROTAC CDK9 degrader-12 (HY-181231). CDK9 ligand 4 is applicable to the research of HIV-1 infection .

HY-182812

Thalidomide-5-F-6-piperidinylpiperazin	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-F-6-piperidinylpiperazin is an ligands for E3 ligase-linker conjugate, which is used for the synthesis of PROTAC CDK9 degrader-9 (HY-168518) .

HY-170980

E3 Ligase Ligand-linker Conjugate 166	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 166 is the conjugate composed of a E3 ligase ligand and a linker. E3 Ligase Ligand-linker Conjugate 166 can be used for synthesis of PROTAC CDK9 degrader-11 (HY-170978) .

HY-181490

WWZ-11-098	PROTACs CDK Apoptosis	Cancer
WWZ-11-098 is a selective CDK6 PROTAC degrader with DC₅₀ of 2.6 nM. WWZ-11-098 induces degradation of CDK6 in a CRBN-dependent manner, while sparing CDK1, CDK2, CDK4, and CDK9. WWZ-11-098 induces apoptosis, G1-S cell cycle arrest and shows anti-proliferative activity in cancer cells. WWZ-11-098 exhibits antitumor efficacy in a xenograft model without signs of toxicity. WWZ-11-098 can be used for the research of leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK9 degrader

Inhibitors & Agonists